AUTHORS
Xu Zhang, PhD, Rima Zahr, DO, MS2, Zalaya Ivy, MD3, Bamidele Tayo, PhD4, Malgorzata Kasztan, PhD5, Sara Rashkin, PhD6, Alexander Bick, MD, PhD7, Deepa Manwani I, MD8, Guolian Other Person Kang, PhD9, Clifford Takemoto, MD10, Mitchell Weiss, MD, PhD11, Victor Gordeuk, MD12, Michael R DeBaun, MD, MPH13, Santosh L Saraf, MD14
AFFILIATIONS
1 University of Illinois Chicago, Chicago, Illinois, United States
2 University of Tennessee Health Science Center, Memphis, Tennessee, United States
3 University of Illinois Chicago, Chicago, Illinois, United States
4 Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, United States
5 University of North Carolina, Chapel Hill, North Carolina, United States
6 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
7 Vanderbilt University, Nashville, Tennessee, United States
8 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
9 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
10 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
11 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
12 University of Illinois Chicago, Chicago, Illinois, United States
13 Vanderbilt University, Nashville, Tennessee, United States
14 University of Illinois Chicago, Chicago, Illinois, United States
ABSTRACT
Sickle cell disease (SCD) and the Apolipoprotein L1 (APOL1) G1 and G2 kidney risk variants evolved to confer protection against P. falciparum malaria and T. brucei rhodesiense sleeping sickness, respectively. Both genetic conditions increase the risk of kidney dysfunction, although not all patients with SCD or high-risk APOL1 develop chronic kidney disease, suggesting additional risk modifiers. In the general population, inflammation augments the risk of APOL1-kidney disease. The purpose of this study was to investigate whether predictors of the degree of hemolysis and related inflammatory stress (hemoglobin [Hb] genotype, α-thalassemia) modify SCD-APOL1 kidney dysfunction risk. We hypothesized that the effects of APOL1 on changes in longitudinal kidney function would be higher in SCD patients coinheriting genetic modifiers associated with more severe hemolysis.
Patients with SCD from 3 academic centers were recruited and genotyped through TOPMed. Baseline and longitudinal data were collected from the electronic medical records. This analysis included 723 unrelated patients aged ≥18 years with serum creatinine values for ≥6 months of follow up. Hb genotype was determined from the medical records, APOL1 (G1 [S342G & I384M], G2 [N388 & Y398 deletions], M1 [p.N264K]) variants were genotyped through TOPMed by Illumina HiSeq X10, and α-3.7 deletion was determined by imputation to 1000 Genomes phase 3 data. Estimated glomerular filtration rate (eGFR) was calculated using the CKD-EPI 2021 equation. The associations of APOL1, Hb genotype, and α-thalassemia with longitudinal eGFR and urine albumin-to-creatinine ratio (uACR) were assessed using linear mixed effects models, which tested time interaction effects for the genotypes and covariates (age, sex, hydroxyurea and chronic transfusion therapy, site, and population stratification), controlling for random intercepts and slopes. Baseline eGFR and uACR were included in the respective slope analyses. Mean ± standard error values are provided.
The median baseline age of the cohort was 24 (range, 18-70) years, 46% were male, 72.1% were HbSS/Sβ0-thalassemia, 21.4% were Hb SC, and 6.5% were Hb Sβ+-thalassemia genotype. Among the 723 enrolled individuals, 14% were high-risk APOL1, 30% had single or double α-3.7 deletion, 50% were on hydroxyurea and 11% were on chronic transfusion therapy. The median follow up was 5.3 (range, 0.5-20) years.
APOL1 N294K M1 variant, which protects against APOL1 G2 kidney risk in the general population, was observed in 5 of 65 SCD patients with APOL1 G1/G2 or G2/G2 and associated with trends for improved kidney function (higher eGFR β 25±15 & lower uACR β -1.4±0.9 at baseline; P≤0.1). In subsequent analyses, the 5 SCD patients coinheriting M1 with APOL1 G2 are reclassified as normal risk.
Hb Genotype: The degree of hemolysis was greater in those with HbSS/Sβ0-thalassemia versus HbSC/Sβ+-thalassemia genotype (reticulocyte: 11.9±6.7% vs. 3.8±1.7%, respectively; Wilcoxon rank-sum P<0.001). Annual eGFR (β -1.5±0.4; P<0.001) and uACR slope (β 0.05±0.03; P=0.065) were steeper in those with HbSS/Sβ0-thalassemia and APOL1 high- versus normal-risk. In those with HbSC/Sβ+-thalassemia, the effect of APOL1 high-risk on eGFR slope was reduced (β -0.7±0.4; P=0.079) and no difference in uACR slope was observed (β -0.003±0.04; P=0.9). An interaction between APOL1 high-risk and Hb genotype for uACR slope was observed (P=0.01).
α-thalassemia: In SCD patients with the HbSS/Sβ0-thalassemia genotype, the degree of hemolysis was greater in those that did not coinherit α-thalassemia versus those with α-thalassemia (reticulocyte: 12.7±7.2% vs. 10.0±5.1%, respectively; Wilcoxon rank-sum P<0.001). Kidney function decline was more rapid in those without α-thalassemia and APOL1 high- versus normal-risk (eGFR β -1.8±0.5; P<0.001; uACR β 0.07±0.03; P=0.02) but not in those with high-risk APOL1 and α-thalassemia (eGFR β -0.68±0.75; P=0.4; uACR: β -0.05±0.08; P=0.5). An interaction between APOL1 high-risk and α-thalassemia for uACR slope was observed (P=0.002).
In conclusion, we show that genotypes associated with reduced hemolysis (HbSC/Sβ+-thalassemia, α-thalassemia) attenuated the deleterious effects of APOL1 risk alleles on kidney function. Our findings help to define the genetic contributors to SCD-associated kidney disease and may guide future strategies for kidney function monitoring and targeted therapies, including APOL1 inhibitors.
DISCLOSURES
Santosh L Saraf, MD: Novartis - Research Funding; Pfizer - Research Funding; Agios Pharmaceuticals, Inc. - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); BEAM Therapeutics - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Chiesi - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony)